Preferences for Attributes of Oral Antipsychotic Treatments: Results From a Discrete-Choice Experiment in Respondents With Schizophrenia or Bipolar I Disorder

Authors

Michael J. Doane, Health Economics and Outcomes Research, Alkermes, Inc., 900 Winter St., Waltham, MA, 02451-1420, USA. michael.doane@alkermes.com.
Marco Boeri, Health Preference Assessment, RTI Health Solutions, Belfast, Northern Ireland, UK.
Caroline Vass, University of Manchester, Manchester, UK.
Cooper Bussberg, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
Hemangi R. Panchmatia, Health Economics and Outcomes Research, Alkermes, Inc., 900 Winter St., Waltham, MA, 02451-1420, USA.
Leslie Citrome, New York Medical College, Valhalla, NY, USA.
Martha Sajatovic, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Author Type(s)

Faculty

DOI

10.1186/s12888-024-06034-1

Journal Title

BMC Psychiatry

First Page

605

Document Type

Article

Publication Date

9-10-2024

Department

Psychiatry and Behavioral Sciences

Abstract

BACKGROUND: Antipsychotic medications are effective treatments for schizophrenia (SZ) and bipolar I disorder (BD-I), but when presented with different treatment options, there are tradeoffs that individuals make between clinical improvement and adverse effects. As new options become available, understanding the attributes of antipsychotic medications that are valued and the tradeoffs that individuals consider when choosing among them is important. METHODS: A discrete-choice experiment (DCE) was administered online to elicit preferences across 5 attributes of oral antipsychotics: treatment efficacy (i.e., improvement in symptom severity), weight gain over 6 months, sexual dysfunction, sedation, and akathisia. Eligible respondents were aged 18-64 years with a self-reported clinician diagnosis of SZ or BD-I. RESULTS: In total, 144 respondents with SZ and 152 with BD-I completed the DCE. Of those with SZ, 50% identified themselves as female and 69.4% as White, with a mean (SD) age of 41.0 (10.1) years. Of those with BD-I, most identified themselves as female (69.7%) and as White (77.6%), with a mean (SD) age of 40.0 (10.7) years. In both cohorts, respondents preferred oral antipsychotics with better efficacy, less weight gain, no sexual dysfunction or akathisia, and lower risk of sedation. Treatment efficacy was the most important attribute, with a conditional relative importance (CRI) of 31.4% for respondents with SZ and 31.0% for those with BD-I. Weight gain (CRI = 21.3% and 23.1%, respectively) and sexual dysfunction (CRI = 23.4% and 19.2%, respectively) were adverse effects in this study that respondents most wanted to avoid. Respondents with SZ were willing to accept 9.8 lb of weight gain or > 25% risk of sedation for symptom improvement; those with BD-I were willing to accept 8.5 lb of weight gain or a > 25% risk of sedation. CONCLUSIONS: In this DCE, treatment efficacy was the most important attribute of oral antipsychotic medications among respondents with SZ and BD-I. Weight gain and sexual dysfunction were the adverse effects respondents most wanted to avoid; however, both cohorts were willing to accept some weight gain or sedation to obtain better efficacy. These results highlight features that patients value in antipsychotic medications and how they balance benefits and risks when choosing among treatments.

Recommended Citation

Doane, M. J., Boeri, M., Vass, C., Bussberg, C., Panchmatia, H. R., Citrome, L., & Sajatovic, M. (2024). Preferences for Attributes of Oral Antipsychotic Treatments: Results From a Discrete-Choice Experiment in Respondents With Schizophrenia or Bipolar I Disorder. BMC Psychiatry, 24 (1), 605. https://doi.org/10.1186/s12888-024-06034-1